Learned by Reading
In the ICWSM 2009 Weblog Corpus:
According to the survey results, more than two – thirds of cardiologists agree that despite lowering LDL levels, a residual risk for cardiovascular events remains.
(Parse)
(S1 (S (PP (VBG According)
(PP (TO to)
(NP (DT the) (NN survey) (NNS results))))
(, ,)
(NP (NP (QP (JJR more) (IN than) (CD two)))
(: -)
(NP (NP (NNS thirds))
(PP (IN of)
(NP (NNS cardiologists)))))
(VP (VBP agree)
(SBAR (IN that)
(S (PP (IN despite)
(NP (VBG lowering) (NN LDL) (NNS levels)))
(, ,)
(NP (NP (DT a) (JJ residual) (NN risk))
(PP (IN for)
(NP (JJ cardiovascular) (NNS events))))
(VP (VBZ remains)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Professor Tobias Kurth, a leading neuroepidemiologist from Harvard Medical School, USA, has found the links between migraine with aura and cardiovascular events are now so strong that GPs need to take them seriously.
(Parse)
(S1 (S (S (NP (NP (NN Professor) (NNP Tobias) (NNP Kurth)) (, ,)
(NP (NP (DT a) (VBG leading) (NN neuroepidemiologist))
(PP (IN from)
(NP (NNP Harvard) (NNP Medical) (NNP School))))
(, ,)
(NP (NNP USA)) (, ,))
(VP (AUX has)
(VP (VBN found)
(NP (NP (DT the) (NNS links))
(PP (IN between)
(NP (NN migraine))))
(PP (IN with)
(NP (NN aura)))
(CC and)
(S (NP (JJ cardiovascular) (NNS events))
(VP (AUX are) (ADVP (RB now))
(ADJP (ADJP (RB so) (JJ strong))
(SBAR (IN that)
(S (NP (NNS GPs))
(VP (AUX need)
(S (VP (TO to)
(VP (VB take)
(NP (PRP them)) (ADVP (RB seriously)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Washington: How much fat a person has is not as important as where it is located, in assessing risk for cardiovascular events and metabolic disease, according to a new study.
(Parse)
(S1 (FRAG (NP (NNP Washington)) (: :)
(SBAR (WHADVP (WRB How) (JJ much) (NN fat))
(S (NP (DT a) (NN person)) (AUX has)
(VP (AUX is) (RB not)
(ADJP (ADJP (RB as) (JJ important))
(PP (IN as)
(SBAR (WHADVP (WRB where))
(S (NP (PRP it))
(VP (AUX is)
(VP (VBN located) (, ,)
(PP (IN in)
(S (VP (VBG assessing)
(NP (NN risk))
(PP (IN for)
(NP (NP (JJ cardiovascular) (NNS events)) (CC and)
(NP (JJ metabolic) (NN disease))))
(, ,)
(PP (VBG according)
(PP (TO to)
(NP (DT a) (JJ new) (NN study))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Medical Research News In the face of a growing obesity epidemic in the United States, researchers at Wake Forest University Baptist Medical Center have new study results that indicate that how much fat a person has is not as important as where that fat is located when assessing risk for cardiovascular events and metabolic disease.
(Parse)
(S1 (S (NP (NNP Medical) (NNP Research) (NNP News))
(PP (IN In)
(NP (NP (DT the) (NN face))
(PP (IN of)
(NP (NP (DT a) (VBG growing) (JJ obesity) (NN epidemic))
(PP (IN in)
(NP (DT the) (NNP United) (NNPS States))))
(, ,)
(NP (NP (NNS researchers))
(PP (IN at)
(NP (NN Wake) (NNP Forest) (NNP University) (NNP Baptist) (NNP Medical) (NNP Center))))
(VP (AUX have)
(NP (NP (JJ new) (NN study) (NNS results))
(SBAR (WHNP (WDT that))
(S (VP (VBP indicate)
(SBAR (IN that) (WHADVP (WRB how) (JJ much) (NN fat))
(S (NP (DT a) (NN person)) (AUX has)
(VP (AUX is) (RB not)
(ADJP (ADJP (RB as) (JJ important))
(PP (IN as)
(SBAR (WHADVP (WRB where))
(S (NP (DT that) (NN fat))
(VP (AUX is)
(VP (VBN located)
(SBAR (WHADVP (WRB when))
(S (VP (VBG assessing)
(NP (NP (NN risk))
(PP (IN for)
(NP (NP (JJ cardiovascular) (NNS events)) (CC and)
(NP (JJ metabolic) (NN disease))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
NSAIDs has collapsed following a multiplicity of observations establishing increased risk for cardiovascular events associated with NSAID use, especially but not uniquely with the new COX – 2 – selective NSAIDs.
(Parse)
(S1 (S (NP (NNS NSAIDs))
(VP (AUX has)
(VP (VBN collapsed)
(PP (VBG following)
(NP (NP (DT a) (NN multiplicity))
(PP (IN of)
(NP (NP (NNS observations))
(VP (VBG establishing)
(NP (NP (VBN increased) (NN risk))
(PP (IN for)
(NP (NP (NP (JJ cardiovascular) (NNS events))
(VP (VBN associated)
(PP (IN with)
(NP (JJ NSAID) (NN use)))
(, ,) (ADVP (RB especially) (CC but) (RB not) (RB uniquely))
(PP (IN with)
(NP (DT the) (JJ new) (NNP COX)))))
(: -)
(NP (CD 2)) (: -)
(NP (JJ selective) (NNS NSAIDs)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
We then followed the group free of CVD at recruitment for 2.72 y (SD = 1.52 y) to learn of new cardiovascular events.
(Parse)
(S1 (S (NP (PRP We)) (ADVP (RB then))
(VP (VBD followed)
(NP (NP (DT the) (NN group))
(ADJP (JJ free)
(PP (IN of)
(NP (NP (NNS CVD))
(PP (IN at)
(NP (NP (NN recruitment))
(PP (IN for)
(NP (NP (CD 2.72) (NNS y)) (PRN (-LRB- -LRB-)
(NP (NN SD) (QP (SYM =) (CD 1.52) (CD y)))
(-RRB- -RRB-))))
(S (VP (TO to)
(VP (VB learn)
(PP (IN of)
(NP (JJ new) (JJ cardiovascular) (NNS events))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Background: Lowering low – density lipoprotein cholesterol with statin therapy results in substantial reductions in cardiovascular events, and larger reductions in cholesterol may produce larger benefits.
(Parse)
(S1 (NP (NP (NN Background)) (: :)
(S (S (VP (VBG Lowering)
(NP (JJ low) (: -) (NN density) (NN lipoprotein) (NN cholesterol))
(PP (IN with)
(NP (NN statin) (NN therapy) (NNS results)))
(PP (IN in)
(NP (NP (NP (JJ substantial) (NNS reductions))
(PP (IN in)
(NP (JJ cardiovascular) (NNS events))))
(, ,) (CC and)
(NP (NP (JJR larger) (NNS reductions))
(PP (IN in)
(NP (NN cholesterol)))))
(VP (MD may)
(VP (VB produce)
(NP (JJR larger) (NNS benefits)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
This post – hoc subanalysis studied the effect of Lipitor 80 mg on the incidence of major cardiovascular events compared with Lipitor 10 mg in patients with heart disease and type 2 diabetes, with chronic kidney disease (n = 546) and without chronic kidney disease (n = 885).
(Parse)
(S1 (NP (NP (DT This) (NN post)) (: -)
(S (NP (FW hoc) (FW subanalysis))
(VP (VBD studied)
(NP (NP (DT the) (NN effect))
(PP (IN of)
(NP (NNP Lipitor) (QP (CD 80) (CD mg))))
(PP (IN on)
(NP (NP (DT the) (NN incidence))
(PP (IN of)
(NP (JJ major) (JJ cardiovascular) (NNS events)))
(PP (VBN compared)
(PP (IN with)
(NP (NP (NP (NNP Lipitor)) (QP (CD 10) (CD mg)))
(PP (IN in)
(NP (NP (NNS patients))
(PP (PP (IN with)
(NP (NP (NN heart) (NN disease)) (CC and)
(NP (NN type) (CD 2) (NN diabetes))))
(, ,)
(PP (IN with)
(NP (NP (JJ chronic) (NN kidney) (NN disease)) (PRN (-LRB- -LRB-)
(NP (NNP n) (SYM =) (CD 546)) (-RRB- -RRB-))))
(CC and)
(PP (IN without)
(NP (NP (JJ chronic) (NN kidney) (NN disease)) (PRN (-LRB- -LRB-)
(NP (NNP n) (SYM =) (CD 885)) (-RRB- -RRB-)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
No serious infections, cardiovascular events, or exacerbation of demyelinating events occurred.
(Parse)
(S1 (S (NP (NP (DT No) (JJ serious) (NNS infections)) (, ,)
(NP (JJ cardiovascular) (NNS events)) (, ,) (CC or)
(NP (NP (NN exacerbation))
(PP (IN of)
(NP (JJ demyelinating) (NNS events)))))
(VP (VBD occurred)) (. .)))
In the ICWSM 2009 Weblog Corpus:
CONCLUSIONS: PEP has an anticancer efficacy equal to CAD and does not increase cardiovascular mortality in metastasized patients, but carries a significant risk of non – fatal cardiovascular events, which should be balanced against the skeletal complications in the CAD group.
(Parse)
(S1 (FRAG (NP (NNS CONCLUSIONS)) (: :)
(S (NP (NN PEP))
(VP (VP (AUX has)
(NP (NP (DT an) (NN anticancer) (NN efficacy))
(ADJP (JJ equal)
(PP (TO to)
(NP (NNP CAD)))
(CC and)
(VP (AUX does) (RB not)
(VP (VB increase)
(NP (JJ cardiovascular) (NN mortality))
(PP (IN in)
(NP (JJ metastasized) (NNS patients)))))
(, ,) (CC but)
(VP (VBZ carries)
(NP (NP (DT a) (JJ significant) (NN risk))
(PP (IN of)
(NP (NN non))))
(: -)
(NP (NP (JJ fatal) (JJ cardiovascular) (NNS events)) (, ,)
(SBAR (WHNP (WDT which))
(S (VP (MD should)
(VP (AUX be)
(VP (VBN balanced)
(PP (IN against)
(NP (NP (DT the) (JJ skeletal) (NNS complications))
(PP (IN in)
(NP (DT the) (NN CAD) (NN group)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
MUNICH, Germany, August 31 / PRNewswire / – Press conference The BEAUTIFUL study: a step further in title Coronary Artery Disease ESC Hotline Title: The BEAUTIFUL study: efficacy of session title ivabradine in reduction of cardiovascular events among patients with stable coronary artery disease and left ventricular dysfunction ESC Hotline 31st August 2008, 11:18 – 11:31 AM session time Press conference 9.00 – 10.00 Timing Executive 31st August 2008: 9.00 – 10.30 AM committee members available for interview The results of the much awaited BEAUTIFUL (morBidity – mortality EvAlUaTion of the IF inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non – fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.
(Parse)
(S1 (FRAG (NP (NNP MUNICH) (, ,) (NNP Germany) (, ,) (NNP August) (CD 31) (NNP /) (NNP PRNewswire) (NNP /)) (: --)
(NP (NNP Press) (NN conference))
(S (S (NP (NP (NP (DT The) (JJ BEAUTIFUL) (NN study)) (: :)
(NP (NP (DT a) (NN step)) (ADVP (RBR further)
(PP (IN in)
(NP (NN title) (JJ Coronary) (NN Artery) (NNP Disease) (NNP ESC) (NNP Hotline) (NNP Title)))))
(: :)
(NP (DT The) (JJ BEAUTIFUL) (NN study)) (: :)
(NP (NN efficacy)))
(PP (IN of)
(NP (NN session) (NN title) (NN ivabradine)))
(PP (IN in)
(NP (NN reduction)))
(PP (IN of)
(NP (JJ cardiovascular) (NNS events)))
(PP (IN among)
(NP (NP (NNS patients))
(PP (IN with)
(NP (JJ stable) (JJ coronary) (NN artery) (NN disease)))
(VP (CC and)
(VP (VBD left)
(NP (JJ ventricular) (NN dysfunction) (NNP ESC) (NNP Hotline))
(NP (JJ 31st) (NNP August) (CD 2008) (, ,) (CD 11:18)))))
(: -)
(S (NP (CD 11:31))
(VP (AUX AM)
(NP (NP (NN session) (NN time))
(NP (NNP Press) (NN conference) (CD 9.00)))
(: -)
(NP (CD 10.00) (NN Timing))
(NP (NNP Executive) (NN 31st) (NNP August) (CD 2008)) (: :)
(NP (CD 9.00)) (: -)
(S (NP (NP (NP (CD 10.30) (NNP AM) (NN committee) (NNS members))
(ADJP (JJ available)
(PP (IN for)
(NP (NP (NN interview))
(SBAR (S (NP (NP (DT The) (NNS results))
(PP (IN of)
(NP (DT the) (JJ much))))
(VP (VBD awaited)
(SBAR (S (NP (JJ BEAUTIFUL) (PRN (-LRB- -LRB-)
(NP (NP (NP (NN morBidity) (: -) (NN mortality) (NN EvAlUaTion))
(PP (IN of)
(NP (NP (DT the))
(PP (IN IF)
(NP (NP (NN inhibitor) (NN ivabradine))
(PP (IN in)
(NP (NP (NNS patients))
(PP (IN with)
(NP (NNP CAD))))
(CC and)
(NP (JJ left) (JJ ventricULar) (NN dysfunction)))
(-RRB- -RRB-)) (NN trial))
(VP (AUX have)
(VP (VBN shown)
(PP (PP (IN that)
(NP (NP (NP (NP (JJ coronary) (NN artery) (NN disease)) (PRN (-LRB- -LRB-)
(NP (NNP CAD)) (-RRB- -RRB-)))
(NNS patients))
(PP (IN with)
(NP (NP (JJ left) (JJ ventricular) (NN dysfunction)) (PRN (-LRB- -LRB-)
(NP (NNP LVD)) (-RRB- -RRB-)) (CC and)
(NP (NP (DT a) (NN heart) (NN rate))
(SBAR (S (NP (QP (JJR more) (IN than) (CD 70)) (NNS bpm))
(VP (AUX have)
(NP (NP (DT a)
(ADJP (RB significantly) (JJR higher)) (NN risk))
(PP (IN of)
(NP (JJ cardiovascular) (NN death)))))
(CC and)
(NP (JJ other) (JJ cardiovascular) (NNS events)))
(CC and)
(PP (IN in)
(NP (NP (DT these) (NNS patients)) (PRN (-LRB- -LRB-)
(NP (NP (NN heart) (NN rate))
(PP (IN above)
(NP (CD 70) (NNS bpm))))
(-RRB- -RRB-)))
(NN treatment))
(PP (IN with)
(NP (NN ivabradine))))
(ADVP (RB further))
(VP (VBZ reduces)
(NP (NP (DT the) (NN risk))
(PP (IN of)
(NP (DT the)
(ADJP (RBS most) (JJ important)) (JJ coronary) (NNS events))))
(PP (JJ such) (IN as)
(ADJP (JJ fatal) (CC and) (JJ non)))
(: -)
(NP (NP (JJ fatal) (JJ myocardial) (NN infarction)) (CC and)
(NP (NP (JJ coronary) (NN revascularisation))
(PP (IN by)
(NP (NP (CD one) (NN third)) (, ,)
(SBAR (WHADVP (RB even) (WRB when))
(S (NP (DT these) (NNS patients))
(VP (AUX are) (ADVP (RB already))
(VP (VBG receiving)
(NP (JJ optimal) (NN therapy)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Patients with a history of drug or alcohol abuse may have a higher chance of celebrex may cause ncreased risk of serious cardiovascular thrombotic events.
(Parse)
(S1 (S (S (NP (NP (NNS Patients))
(PP (IN with)
(NP (NP (DT a) (NN history))
(PP (IN of)
(NP (NN drug) (CC or) (NN alcohol) (NN abuse)))
(VP (MD may)
(VP (AUX have)
(NP (NP (DT a) (JJR higher) (NN chance))
(PP (IN of)
(NP (NN celebrex))))
(VP (MD may)
(VP (VB cause)
(NP (NP (JJ ncreased) (NN risk))
(PP (IN of)
(NP (JJ serious) (JJ cardiovascular) (JJ thrombotic) (NNS events)))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Reductions in these two risk factors may help protect against heart attacks and other cardiovascular events.
(Parse)
(S1 (S (NP (NP (NNS Reductions))
(PP (IN in)
(NP (DT these) (CD two) (NN risk) (NNS factors))))
(VP (MD may)
(VP (VB help)
(VP (VB protect)
(PP (IN against)
(NP (NP (NN heart) (NNS attacks)) (CC and)
(NP (JJ other) (JJ cardiovascular) (NNS events))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
In the AEMS substudy, during the first 42 days after vaccination, the rate of overall cardiovascular events was higher after 0.6 % after Zostavax versus 0.4 % after placebo.
(Parse)
(S1 (S (PP (IN In)
(NP (DT the) (NNP AEMS) (NN substudy)))
(, ,)
(PP (IN during)
(NP (NP (DT the) (JJ first) (CD 42) (NNS days))
(PP (IN after)
(NP (NN vaccination)))))
(, ,)
(NP (NP (DT the) (NN rate))
(PP (IN of)
(NP (JJ overall) (JJ cardiovascular) (NNS events))))
(VP (AUX was)
(ADJP (JJR higher))
(PP (IN after)
(NP (NP (NP (CD 0.6) (NN %))
(PP (IN after)
(NP (NNP Zostavax))))
(CC versus)
(NP (NP (CD 0.4) (NN %))
(PP (IN after)
(NP (NN placebo))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
CONCLUSIONS: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes.
(Parse)
(S1 (NP (NP (NNS CONCLUSIONS)) (: :)
(S (NP (NP (NN Therapy))
(PP (IN with)
(NP (NN telmisartan)))
(VP (VP (VBN initiated)
(PP (ADVP (RB soon)) (IN after)
(NP (DT an) (JJ ischemic) (NN stroke))))
(CC and)
(VP (VBN continued)
(PP (IN for)
(NP (CD 2.5) (NNS years)))
(VP (AUX did) (RB not)
(VP (ADVP (RB significantly)) (VB lower)
(NP (NP (DT the) (NN rate))
(PP (IN of)
(NP (NP (JJ recurrent) (NN stroke)) (, ,)
(NP (JJ major) (JJ cardiovascular) (NNS events)) (, ,) (CC or)
(NP (NN diabetes)))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Medical Research News In the face of a growing obesity epidemic in the United States, researchers at Wake Forest University Baptist Medical Center have new study results that indicate that how much fat a person has is not as important as where that fat is located when assessing risk for cardiovascular events and metabolic disease.
(Parse)
(S1 (S (NP (NNP Medical) (NNP Research) (NNP News))
(PP (IN In)
(NP (NP (DT the) (NN face))
(PP (IN of)
(NP (NP (DT a) (VBG growing) (JJ obesity) (NN epidemic))
(PP (IN in)
(NP (DT the) (NNP United) (NNPS States))))
(, ,)
(NP (NP (NNS researchers))
(PP (IN at)
(NP (NN Wake) (NNP Forest) (NNP University) (NNP Baptist) (NNP Medical) (NNP Center))))
(VP (AUX have)
(NP (NP (JJ new) (NN study) (NNS results))
(SBAR (WHNP (WDT that))
(S (VP (VBP indicate)
(SBAR (IN that) (WHADVP (WRB how) (JJ much) (NN fat))
(S (NP (DT a) (NN person)) (AUX has)
(VP (AUX is) (RB not)
(ADJP (ADJP (RB as) (JJ important))
(PP (IN as)
(SBAR (WHADVP (WRB where))
(S (NP (DT that) (NN fat))
(VP (AUX is)
(VP (VBN located)
(SBAR (WHADVP (WRB when))
(S (VP (VBG assessing)
(NP (NP (NN risk))
(PP (IN for)
(NP (NP (JJ cardiovascular) (NNS events)) (CC and)
(NP (JJ metabolic) (NN disease))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
The primary endpoint of the SEAS study was’ ’ major cardiovascular events’ ’, which is the composite of events associated with aortic valve disease and with atherosclerotic disease.
(Parse)
(S1 (S (NP (DT The) (JJ primary)
(ADJP (JJ endpoint)
(PP (IN of)
(NP (DT the) (NNS SEAS))))
(NN study))
(VP (AUX was)
(VP (POS ') ('' ')
(NP (JJ major) (JJ cardiovascular) (NNS events)) ('' ') ('' ') (, ,)
(SBAR (WHNP (WDT which))
(S (VP (AUX is)
(NP (NP (DT the) (NN composite))
(PP (IN of)
(NP (NP (NNS events))
(VP (VBN associated)
(PP (PP (IN with)
(NP (JJ aortic) (NN valve) (NN disease)))
(CC and)
(PP (IN with)
(NP (JJ atherosclerotic) (NN disease))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Increased urinary albumin is a predictor of renal failure, type 1 and type 2 diabetes; it correlates closely with mean arterial pressure in hypertensive subjects, predicts cardiovascular events and has a strong association with the metabolic syndrome.
(Parse)
(S1 (S (S (NP (VBN Increased) (JJ urinary) (NN albumin))
(VP (AUX is)
(NP (NP (DT a) (NN predictor))
(PP (IN of)
(NP (NP (JJ renal) (NN failure)) (, ,)
(NP (NN type) (CD 1)) (CC and)
(NP (NN type) (CD 2) (NN diabetes))))
(: ;)
(S (NP (PRP it))
(VP (VP (VBZ correlates) (ADVP (RB closely))
(PP (IN with)
(NP (JJ mean) (JJ arterial) (NN pressure)))
(PP (IN in)
(NP (JJ hypertensive) (NNS subjects))))
(, ,)
(VP (VBZ predicts)
(NP (JJ cardiovascular) (NNS events)))
(CC and)
(VP (VBZ has)
(NP (NP (DT a) (JJ strong) (NN association))
(PP (IN with)
(NP (DT the) (JJ metabolic) (NN syndrome))))
(. .)))
In the ICWSM 2009 Weblog Corpus:
Since renin – angiotensin system inhibitors or a lipid – lowering agent, atorvastatin, not only inhibit the AGE – signaling to inflammation, but also reduce serum levels of AGEs in type 2 diabetic patients, it is conceivable that the carry – over beneficial effects of multifactorial intervention on cardiovascular events and death in the follow – up Steno – 2 Study could be ascribed, at least in part, to its inhibitory effects on AGE formation and / or the downstream – signaling pathways.
(Parse)
(S1 (S (SBAR (IN Since)
(S (S (NP (NP (NN renin)) (: -)
(NP (NP (NN angiotensin) (NN system) (NNS inhibitors)) (CC or)
(NP (DT a) (NN lipid)))
(: -)
(NP (VBG lowering) (NN agent)) (, ,)
(NP (NN atorvastatin)) (, ,)) (ADVP (RB not) (RB only))
(VP (VB inhibit)
(NP (DT the) (NN AGE))))
(: -)
(S (VP (VBG signaling)
(PP (TO to)
(NP (NN inflammation)))))
(, ,) (CC but)
(S (ADVP (RB also))
(VP (VB reduce)
(NP (NP (NN serum) (NNS levels))
(PP (IN of)
(NP (NNS AGEs))))
(PP (IN in)
(NP (NN type) (CD 2) (NNP diabetic) (NNS patients))))
(, ,)
(NP (PRP it))
(VP (AUX is)
(ADJP (JJ conceivable)
(SBAR (IN that)
(S (NP (NP (DT the) (NN carry)) (: -)
(PP (IN over)
(NP (NP (JJ beneficial) (NNS effects))
(PP (IN of)
(NP (JJ multifactorial) (NN intervention)))
(PP (IN on)
(NP (NP (JJ cardiovascular) (NNS events) (CC and) (NN death))
(PP (IN in)
(NP (DT the) (VB follow))))
(: -)
(ADJP (RB up) (JJ Steno)) (: -)
(NP (CD 2) (NN Study)))
(VP (MD could)
(VP (AUX be)
(VP (VBN ascribed) (, ,)
(PP (ADVP (IN at) (JJS least)) (IN in)
(NP (NN part)))
(, ,)
(PP (TO to)
(NP (NP (PRP$ its) (JJ inhibitory) (NNS effects))
(PP (IN on)
(NP (NP (NN AGE) (NN formation) (CC and) (NN /)) (CC or)
(NP (DT the) (JJ downstream)))
(: -)
(S (VP (VBG signaling)
(NP (NNS pathways)))))
(. .)))
And 666 more sentences.